{"id":"W4382022426","doi":"10.1002/jvc2.203","title":"Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials","year":2023,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health; Queen's University","funders":"LEO Pharma; EMD Serono; Bausch Health; Genentech; Coherus Biosciences; Dermira; Castle Biosciences; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Sanofi; Amgen; Pfizer; Celgene; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Post-hoc analysis; Systemic therapy; Internal medicine; Clinical endpoint; Clinical trial; Placebo; Regimen; Adverse effect; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009349899,0.000873741,0.003202788,0.0005696236,0.0003111508,0.001207678,0.000587534,0.0006467165,0.003334715],"category_scores_gemma":[0.007000424,0.0003211048,0.00586518,0.0006089447,0.0004967279,0.0008719492,0.000519097,0.001183913,0.0003283682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005309659,"about_ca_system_score_gemma":0.0011383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002962809,"about_ca_topic_score_gemma":0.0009227124,"domain_scores_codex":[0.9936687,0.004414271,0.000580625,0.0006130186,0.0004292114,0.0002941631],"domain_scores_gemma":[0.9917594,0.005524021,0.001328612,0.0006262662,0.0003855765,0.0003761704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.8515627,0.002349824,0.06276289,0.00225478,0.04548158,0.0003008361,0.0001230498,0.00207961,0.005418106,0.0002771225,0.002360246,0.02502914],"study_design_scores_gemma":[0.3898036,0.2045905,0.3060519,0.0004287575,0.0701035,0.001272485,0.0003684479,0.007648185,0.006698783,0.0008314178,0.01204267,0.0001598057],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856387,0.008090714,0.0006744551,0.0001856412,0.0001264268,0.0009225806,0.002212554,0.00002847157,0.002120502],"genre_scores_gemma":[0.9943888,0.001162946,0.0006447295,0.0002343067,0.0001510955,0.0007699253,0.001777992,0.00001322688,0.0008569431],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009349899,"threshold_uncertainty_score":0.0494476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07817612280527099,"score_gpt":0.4291313892612185,"score_spread":0.3509552664559475,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}